Search
Fluspirilene
go.drugbank.com/drugs/DB04842ApprovedWithdrawnA long-acting injectable antipsychotic agent used for chronic schizophrenia.
Categories: Dopamine D2 Receptor Antagonists, Cytochrome P-450 SubstratesOcadusertib
go.drugbank.com/drugs/DB21732InvestigationalOcadusertib has a monoisotopic molecular weight of 459.19 Da. … Ocadusertib is under investigation in clinical trial NCT05848258 (An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis).
Etidronic acid
go.drugbank.com/drugs/DB01077ApprovedInvestigationalEtidronic acid is a first generation bisphosphonate similar to clodronic acid and tiludronic acid. These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification. Etidronate’s use has de...
Linaprazan glurate
go.drugbank.com/drugs/DB21534InvestigationalLinaprazan glurate has a monoisotopic molecular weight of 480.24 Da. … Linaprazan glurate is under investigation in clinical trial NCT07037875 (A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due
Tengonermin
go.drugbank.com/drugs/DB16689InvestigationalTengonermin, also known as NGR-hTNF, is a vascular-targeting drug. It is a recombinant protein and peptide-targeted agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. This drug works by mod...
Darusentan
go.drugbank.com/drugs/DB04883InvestigationalDarusentan is a selective endothelin ETA receptor antagonist. It is being evaluated as a treatment for congestive heart failure and hypertension.
Trimethobenzamide
go.drugbank.com/drugs/DB00662ApprovedInvestigationalTrimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic respon...
Elexacaftor
go.drugbank.com/drugs/DB15444ApprovedInvestigational[A187361] Elexacaftor, along with [VX-659], was designed to fill the need for an efficacious CF therapy for patients who are heterozygous for _F508del-CFTR_ and a gene that does not produce protein or
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSotagliflozin
go.drugbank.com/drugs/DB12713ApprovedInvestigational[L39739] On March 22, 2022, the marketing authorization of sotagliflozin for the treatment of type 1 diabetes mellitus was withdrawn by the EMA due to commercial reasons. … Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind,[A244499] which is approved for use in the EU, in combination with insulin, to improve glycemic control in patients with type
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesMaribavir
go.drugbank.com/drugs/DB06234ApprovedInvestigationalMaribavir is an inhibitor of the cytomegalovirus (CMV; HHV5) pUL97 kinase which is used to treat CMV infections in patients post-transplantation. … [A242557] Maribavir is novel in that it instead targets the CMV pUL97 kinase, thereby providing an effective alternative treatment option in cases of resistant infections.
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors